Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

Journal of Clinical Oncology

Volumn 23, Issue 11, 2005, Pages 2445-2459

  Baselga, José ^a   Arteaga, Carlos L ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; MATUZUMAB; MONOCLONAL ANTIBODY; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; COLORECTAL CARCINOMA; GENE AMPLIFICATION; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; MEDICAL RESEARCH; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 17844372539     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.890     Document Type: Review

References (133)

1. Manning G, Whyte DB, Martinez R, et al: The protein kinase complement of the human genome. Science 298:1912-1934, 2002
2. Robinson DR, Wu YM, Lin SF: The protein tyrosine kinase family of the human genome. Oncogene 19:5548-5557, 2000
3. Kawamoto T, Sato JD, Le A, et al: Growth stimulation of A431 cells by EGF: Identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A 80:1337-1341, 1983
4. Sato JD, Kawamoto T, Le AD, et al: Biological effect in vitro of monoclonal antibodies to human EGF receptors. Mol Biol Med 1:511-529, 1983
5. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787-2799, 2003
6. Goldstein NI, Prewett M, Zuklys K, et al: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311-1318, 1995
7. Rubin M, Shin D, Pasmantier M, et al: Monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFR), for patients with EGFR-positive tumors refractory to or in relapse from previous therapeutic regimens. Proc Am Soc Clin Oncol 19:479a, 2000 (abstr 1860)
8. Prewett MC, Hooper AT, Bassi R, et al: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8:994-1003, 2002
9. Saltz L, Rubin M, Hochster H, et al: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20:3a, 2001 (abstr 7)
10. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
11. Saltz LB, Meropol NJ, Loehrer PJ, Sr., et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004
12. Tabernero JM, Van Cutsem E, Sastre J, et al: An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. Proc Am Soc Clin Oncol 23:248, 2004 (abstr 3512)
13. Hecht JR, Patnaik A, Malik I, et al: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. Proc Am Soc Clin Oncol 23:248, 2004 (abstr 3511)
14. Salazar R, Tabernero J, Rojo F, et al: Dose-dependent inhibition of the EGFR and signaling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/ pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). Proc Am Soc Clin Oncol 23:127, 2004 (abstr 2002)
15. Vanhoefer U, Tewes M, Rojo F, et al: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22:175-184, 2004
16. Shin DM, Donato NJ, Perez-Soler R, et al: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7:1204-1213, 2001
17. Kim ES, Mauer AM, Fossella FV, et al: A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:293a, 2002 (abstr 1168)
18. Baselga J, Trigo JM, Bourthis J, et al: Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum based agent. Proc Am Soc Clin Oncol 21:226a, 2002 (abstr 900)
19. Trigo J, Hitt R, Koralewski P, et al: Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. Proc Am Soc Clin Oncol 23:487, 2004 (abstr 5502)
20. Leon X, Hitt R, Constenla M, et al: A retrospective analysis of the outcome of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) who are progressing while on a platinum-based palliative chemotherapy. Proc Am Soc Clin Oncol 22:502, 2003 (abstr 2022)
21. Bonner JA, Harari PM, Giralt J, et al: Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. Proc Am Soc Clin Oncol 23: 5507, 2004
22. Crombet T, Osorio M, Cruz T, et al: Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22:1646-1654, 2004
23. Rosell R, Daniel C, Ramlau R, et al: Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 23:618, 2004 (abstr 7012)
24. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002
25. Agus DB, Gordon MS, Taylor C, et al: A phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534-2543, 2005
26. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
27. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
28. Perez-Soler R, Chachoua A, Huberman M, et al: A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:310a, 2001 (abstr 1235)
29. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 22:777-784, 2004
30. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 22:785-794, 2004
31. Herbst RS, Prager D, Hermann R, et al: TRIBUTE - A phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 23:7011, 2004
32. Gatzemeier U, Pluzanska A, Szczesna A, et al: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 22:617, 2004 (abstr 7010)
33. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
34. Baselga J, Rischin D, Ranson M, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302, 2002
35. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
36. Pao W, Miller VA: EGFR mutations, small molecule kinase inhibitors, and non-small cell lung cancer: Current knowledge and future directions. J Clin Oncol 23:2556-2568, 2005
37. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
38. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
39. Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513-2520, 2005
40. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798-3807, 2003
41. Cappuzzo F, Magrini E, Bartolini S, et al: Improved efficacy of gefitinib therapy in phospho-Akt positive patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 23:196, 2004 (abstr 3004)
42. Rusnak DW, Lackey K, Affleck K, et al: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1:85-94, 2001
43. Wood ER, Truesdale AT, McDonald OB, et al: A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64:6652-6659, 2004
44. Spector NL, Xia W, Burris H, III, et al: A study of the biological effects of lapatinib (GW572016), a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23:2502-2512, 2005
45. Blackwell KL, Kaplan EH, Franco SX, et al: A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 23:196, 2004 (abstr 3006)
46. Burstein H, Storniolo AM, Franco S, et al: A phase II, open-label, multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens. Ann Oncol 15:2004 (abstr 1040; suppl 3)
47. Traxler P, Allegrini PR, Brandt R, et al: AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64:4931-4941, 2004
48. Weinstein IB: Cancer. Addiction to oncogenes - The Achilles heal of cancer. Science 297:63-64, 2002
49. Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64:8919-8923, 2004
50. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to geftinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109, 2004
51. Shepherd FA, Pereira J, Ciuleanu TE, et al: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Oncol 23:7022, 2004
52. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib and erlotinib. PLoS Med: 57-61, 2005
53. Sordella R, Bell DW, Haber DA, et al: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163-1167, 2004
54. Rodriguez-Viciana P, Warne PH, Dhand R, et al: Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532, 1994
55. Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554, 2004
56. Campbell IG, Russell SE, Choong DYH, et al: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678-7681, 2004
57. Bachman K, Argani P, Samuels Y, et al: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3:772-775, 2004
58. Stephens P, Hunter C, Bignell G, et al: Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431:525-526, 2004
59. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914, 2000
60. Albanell J, Codony-Servat J, Rojo F, et al: Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61:6500-6510, 2001
61. Albanell J, Rojo F, Averbuch S, et al: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124, 2002
62. Stoll S, Benedict M, Mitra R, et al: EGF receptor signaling inhibits keratinocyte apoptosis: Evidence for mediation by Bcl-XL. Oncogene 16:1493-1499, 1998
63. Jost M, Kari C, Rodeck U: The EGF receptor - An essential regulator of multiple epidermal functions. Eur J Dermatol 10:505-510, 2000
64. Malik SN, Siu LL, Rowinsky EK, et al: Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 9:2478-2486, 2003
65. Hoeskstra RDH: A phase I and pharmacological study of intermitent dosing of PKI 166, a novel EGFR tyrosine kinase inhibitor administered orally to patients with advanced cancer. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, Miami, FL, 2001
66. Zinner RG, Nemunaitis JJ, Donato NJ, et al: A phase I clinical and biomarker study of the novel pan-erbB tyrosine kinase inhibitor, Cl-1033, in patients with solid tumors. Proceedings AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, Miami, FL, 2001, pp 566
67. Baselga J, Albanell A, Ruiz A, et al: Phase II and tumor pharmacodynamic study of gefinitib (ZD1839) in patients with advanced breast cancer. Proc Am Soc Clin Oncol 22:7, 2003 (abstr 24)
68. Tabernero J, Rojo F, Marimón I, et al: A phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. J Clin Oncol 23:2521-2533, 2005
69. Assersohn L, Salter J, Powles TJ, et al: Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat 82:113-123, 2003
70. Dowsett M, Smith I, Ebbs SR, et al: Short term changes in Ki67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Lancet: in press
71. Baum M, Buzdar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
72. Dowsett M, Smith IE, Ebbs SR, et al: Biomarker changes during neoadjuvant anastrozole, tamoxifen or the combination: Influence of hormonal status and HER2 in breast cancer. J Clin Oncol 23:2477-2492, 2005
73. Ellis MJ, Coop A, Singh B, et al: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression. Cancer Res 63:6523-6531, 2003
74. Mohsin SK, Weiss HL, Gutierrez MC, et al: Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23:2460-2468, 2005
75. Cordon-Cardo C, Kotsianti A, Donovan MJ, et al: Improved prediction of PSA recurrence through systems pathology. Proc Am Soc Clin Oncol 23:403, 2004 (abstr 4591)
76. Camp RL, Chung GG, Rimm DL: Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8:1323-1327, 2002
77. Matar P, Rojo F, Cassia R, et al: Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting. Clin Cancer Res 10:6487-6501, 2004
78. Liotta LA, Espina V, Mehta AI, et al: Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell 3: 317-325, 2003
79. Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998
80. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001
81. Pegram MD, Konecny GE, O'Callaghan C, et al: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739-749, 2004
82. Burstein HJ, Harris LN, Marcom PK, et al: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21:2889-2895, 2003
83. Pegram MD, Pienkowski T, Northfelt DW, et al: Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96:759-769, 2004
84. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
85. Sirotnak FM, Zakowsky MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenographs is markedly enhanced by coadministration of ZD1839 ('Iressa') an inhibitor of tyrosine kinase. Clin Cancer Res 6:4885-4892, 2000
86. Ciardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063, 2000
87. Baselga J: Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: How do we go from INTACT to impact? J Clin Oncol 22:759-761, 2004
88. Albain KS, Green SJ, Ravdin PM, et al: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21:37a, 2002 (abstr 143)
89. Ahrendt SA, Decker PA, Alawi EA, et al: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92:1525-1530, 2001
90. Huang SM, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935-1940, 1999
91. Harari PM, Huang SM: Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49:427-433, 2001
92. Fan Z, Baselga J, Masui H, et al: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53:4637-4642, 1993
93. van de Vijver MJ, He YD, van 't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002
94. Pusztai L, Ayers M, Simmans FW, et al: Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Proc Am Soc Clin Oncol 22:1, 2003 (abstr 1)
95. Tabernero J, Rojo F, Jimenez E, et al: A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc Am Soc Clin Oncol 22:192, 2003 (abstr 770)
96. Khambata Ford S, Perkins N-A, Yoganathan S, et al: Pharmacogenomic approaches for identifying markers predictive of tumor response to Cetuximab (Erbitux). Proc Am Assoc Cancer Res 45:2004 (abstr 2032)
97. Natale RB, Shak S, Aronson N, et al: Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: Predicting response to gefitinib, an EGFR kinase inhibitor. Proc Am Soc Clin Oncol 22:190, 2003 (abstr 763)
98. Albain K, Elledge R, Gradishar WJ, et al: Open-label, phase II, multicenter trial of ZD1839 (Iressa) in patients with advanced breast cancer. Breast Cancer Res Treat 76:S33, 2002 (abstr 20; suppl 1)
99. Robertson JFR, Gutteridge E, Cheung KL, et al: Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant estrogen receptor (ER)-positive and ER-negative breast cancer: Results from a phase II study. Proc Am Soc Clin Oncol 22:7, 2003 (abstr 23)
100. Tan AR, Yang X, Hewitt SM, et al: Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 22:3080-3090, 2004
101. Nicholson RI, Hutcheson IR, Knowlden JM, et al: Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 10:346S-354S, 2004
102. Nicholson R, Hutcheson I, Harper M, et al: Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 8:175-182, 2001
103. Massarweh S, Shou J, Dipietro M, et al: Targeting the epidermal growth factor receptor pathway improves the anti-tumor effect of tamoxifen and delays acquired resistance in a xenograft model of breast cancer. Breast Cancer Res Treat 76:S33, 2002 (abstr 18; suppl 1)
104. Osborne CK, Bardou V, Hopp TA, et al: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361, 2003
105. Shou J, Massarweh S, Osborne CK, et al: Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/ HER2-positive breast cancer. J Natl Cancer Inst 96:926-935, 2004
106. Gschwind A, Fischer OM, Ullrich A: The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 4:361-370, 2004
107. Karunagaran D, Tzahar E, Beerli RR, et al: ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15:254-264, 1996
108. Muller W, Arteaga C, Muthuswamy S, et al: Synergistic interaction of the neu proto-oncogene product and transforming growth factor α in the mammary epithelium of transgenic mice. Mol Cell Biol 16:5726-5736, 1996
109. Xia W, Lau Y-K, Zhang H-Z, et al: Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5:4164-4174, 1999
110. Tateishi M, Ishida T, Kohdono S, et al: Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg Oncol 3:109-113, 1994
111. Qian X, Dougall WC, Hellman ME, et al: Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation. Oncogene 9:1507-1514, 1994
112. Graus-Porta D, Beerli RR, Hynes NE: Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 15:1182-1191, 1995
113. Christensen JG, Schreck RE, Chan E, et al: High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res 7:4230-4238, 2001
114. Motoyama AB, Hynes NE, Lane HA: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62:3151-3158, 2002
115. Ye D, Mendelsohn J, Fan Z: Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18:731-738, 1999
116. Moasser MM, Basso A, Averbuch SD, et al: The tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61:7184-7188, 2001
117. Moulder SL, Yakes M, Muthuswamy SK, et al: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/Neu (erb-2)- overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895, 2001
118. Normanno N, Campiglio M, De Luca A, et al: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13:65-72, 2002
119. Arteaga CL, O'Neil A, Moulder SL, et al: ECOG1100: A phase I-II study of combined blockade of the erbB receptor network with trastuzmab and gefitinib (Iressa) in patients (pts) with HER2-overexpressing metastatic breast cancer (met br ca). 27th San Antonio Breast Cancer Symposium, San Antonio, TX, December 2004 (abstr 24)
120. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
121. Baselga J, Carbonell X, Castaneda-Soto N-J, et al: Efficacy, safety and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule: A phase II study. J Clin Oncol 23: in press
122. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-EGFR therapy in primary human glioblastoma cells trough continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62:200-207, 2002
123. Lu Y, Zi X, Zhao Y, et al: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-1857, 2001
124. Garcia-Echeverria C, Pearson MA, Marti A, et al: In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5:231-239, 2004
125. Bianco R, Shin I, Ritter CA, et al: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812-2822, 2003
126. Di Cosimo S, Matar P, Rojo F, et al: Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001). Proc Am Soc Clin Oncol 23:213b, 2004 (abstr 3074)
127. Hanahan D, Weinberg R: The hallmarks of cancer. Cell 100:57-70, 2000
128. Petit AM, Rak J, Hung MC, et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530, 1997
129. Ciardiello F, Caputo R, Bianco R, et al: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7: 1459-1465, 2001
130. Viloria-Petit A, Crombet T, Jothy S, et al: Acquired resistance to the antitumor effect of EGFR-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61: 5090-5101, 2001
131. Herbst RS, Johnson DH, Mininberg E, et al: Phase I/II trial evaluating the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, for patients with recurrent non-small cell lung cancer. J Clin Oncol 23:2544-2555, 2005
132. Pegram MD, Yeon C, Ku NC, et al: Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). 27th San Antonio Breast Cancer Symposium, San Antonio, TX, December 2004 (abstr 3039)
133. Wedge SR, Ogilvie DJ, Dukes M, et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645-4655, 2002